<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacologic treatment and prevention of high-altitude illness (HAI)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacologic treatment and prevention of high-altitude illness (HAI)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pharmacologic treatment and prevention of high-altitude illness (HAI)</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="10%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="2">Condition</td> <td class="subtitle1_left">Preferred agent</td> <td class="subtitle1_left">Alternatives</td> </tr> <tr> <td rowspan="4"><strong>AMS/HACE</strong></td> <td>Prevention*</td> <td> <p><strong>Acetazolamide</strong></p> <p>Adults: 125 mg orally every 12 hours</p> <p>Children: 2.5 mg/kg (maximum single dose: 125 mg) orally every 12 hours<sup>¶</sup></p> Duration: Start day before ascent and continue 2 to 3 days at maximum altitude; may use once at night thereafter to improve sleep</td> <td> <p><strong>Dexamethasone</strong></p> <p>Adults: 2 mg orally every 6 hours or 4 mg orally every 12 hours</p> <p>Children: Acetazolamide preferred; do not use for prophylaxis</p> Duration: Start day of ascent and continue 2 to 3 days at maximum altitude but for no more than 7 days total</td> </tr> <tr> <td>Treatment of mild AMS<sup>Δ</sup></td> <td> <p><strong>Acetazolamide</strong></p> <p>Adults: 125 to 250 mg orally every 12 hours</p> <p>Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours<sup>¶</sup></p> Duration: Continue for 24 hours after symptoms resolve or descent completed</td> <td> <p><strong>Dexamethasone</strong></p> <p>Adults: 2 to 4 mg orally every 6 hours</p> <p>Children: 0.15 mg/kg (maximum single dose: 4 mg) orally every 6 hours</p> Duration: Continue until 24 hours after symptoms resolve or descent completed but for no more than 7 days total</td> </tr> <tr> <td>Treatment of moderate to severe AMS</td> <td> <p><strong>Dexamethasone</strong><sup>◊</sup></p> <p>Adults: 4 mg orally every 6 hours</p> <p>Children: 0.15 mg/kg (maximum single dose: 4 mg) orally every 6 hours</p> Duration: Continue for 24 hours after symptoms resolve or descent completed but for no more than 7 days total</td> <td> <p><strong>Acetazolamide</strong></p> <p>Adults: 125 to 250 mg orally every 12 hours</p> <p>Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours<sup>¶</sup></p> Duration: Continue for 24 hours after symptoms resolve or descent completed</td> </tr> <tr> <td>Treatment of HACE</td> <td> <p><strong>Dexamethasone</strong><sup>◊</sup></p> <p>Adults: 8 to 10 mg orally/IM/IV once, then 4 mg orally/IM/IV every 6 hours</p> <p>Children: 0.15 mg/kg (maximum single dose: 4 mg) every 6 hours</p> Duration: Continue until 24 hours after symptoms resolve or descent completed but for no more than 7 days total</td> <td> <p><strong>Acetazolamide</strong></p> <p>Adults: 250 mg orally every 12 hours; may use as adjunct with dexamethasone; <strong>not</strong> for monotherapy</p> <p>Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours<sup>¶</sup></p> Duration: Continue until 24 hours after symptoms resolve or descent completed</td> </tr> <tr> <td rowspan="2"><strong>HAPE</strong></td> <td>Prevention*</td> <td> <p><strong>Nifedipine</strong></p> <p class="indent1">Adults and children ≥50 kg: 30 mg extended-release orally every 12 hours</p> <p class="indent1">Duration: Start day before ascent and continue for 5 days at maximum altitude</p> <p><strong>Acetazolamide</strong></p> <p class="indent1">Pediatric re-entry HAPE prevention only (&lt;50 kg): 2.5 mg/kg (maximum single dose: 125 mg) orally every 12 hours<sup>¶</sup></p> <p class="indent1 extra_spacing_top">Duration: Start day before ascent and continue 4 to 5 days at maximum altitude</p> </td> <td> <p>Further research is needed before the medications listed below can be recommended for routine use in HAPE prevention (adult dosing):</p> <p class="indent1"><strong>Tadalafil:</strong> 10 mg orally every 12 hours; start day of ascent and continue 3 to 5 days at maximum altitude</p> <p class="indent1"><strong>Sildenafil:</strong> 50 mg orally every 8 hours; start day of ascent and continue 3 to 5 days at maximum altitude</p> <p class="indent1"><strong>Dexamethasone:</strong> 8 mg orally every 12 hours; start day of ascent and continue 48 to 72 hours at maximum altitude</p> <p class="indent1 extra_spacing_top"><strong>Acetazolamide:</strong> 125 to 250 mg orally every 12 hours; start day before ascent and continue 48 to 72 hours at maximum altitude</p> </td> </tr> <tr> <td>Treatment<sup>§</sup></td> <td> <p><strong>Nifedipine</strong></p> <p class="indent1">Adults and children ≥50 kg: 30 mg extended-release orally every 12 hours</p> <p><strong>Amlodipine</strong><sup>¥</sup></p> <p class="indent1">Children 6 to 17 years old and ≥25 kg: 2.5 to 5 mg orally once daily</p> <p class="indent1">Children 1 to 5 years old or &lt;25 kg: 0.1 to 0.6 mg/kg/dose orally once daily (maximum 5 mg/day); oral liquid available</p> Duration (both agents): Continue until descent completed, symptoms resolved, and SpO<sub>2</sub> normal for altitude</td> <td> <p>Further research is needed before the medications listed below can be recommended for routine use in HAPE treatment (adult dosing):</p> <p class="indent1"><strong>Tadalafil:</strong> 10 mg orally every 12 hours</p> <p class="indent1"><strong>Sildenafil:</strong> 50 mg orally every 8 hours</p> Duration: Continue until descent completed, symptoms resolved, and SpO<sub>2</sub> normal for altitude</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>AMS: acute mountain sickness; HACE: high-altitude cerebral edema; HAPE: high-altitude pulmonary edema; IM: intramuscularly; IV: intravenously; NSAID: nonsteroidal antiinflammatory drug; HAI: high-altitude illness; SpO<sub>2</sub>: oxygen saturation.</p>
<p>* Gradual ascent is the best strategy for prevention of HAI. Early recognition of symptoms and prompt treatment are critical to reduce risk of progression to serious HAI (such as HAPE and HACE). Reserve pharmacologic prophylaxis for patients who have a history of HAPE or recurrent AMS and patients at high risk (as well as selected patients at moderate risk) of developing AMS/HACE according to criteria listed in the separate UpToDate content. Refer to UpToDate content on unique pediatric considerations for discussion on prevention in children. Provision of these medications for "rescue" treatment is also reasonable.</p>
<p>¶ For immediate administration in children, a liquid acetazolamide solution can be made by crushing a 125 mg or 250 mg tablet and suspending it in cherry, chocolate, or other flavored syrup to hide the bitter taste. A flavored oral suspension useful in patients who cannot swallow pills or for measurement of doses used in smaller children (eg &lt;125 mg) can also be compounded by a pharmacy. Detail is available in the acetazolamide pediatric drug monograph.</p>
<p>Δ May not require pharmacologic treatment. Rest, halt ascent, and symptomatic treatment (eg, acetaminophen or NSAID for headache and ondansetron for nausea/vomiting) may be sufficient. Refer to accompanying UpToDate text.</p>
<p>◊ Treatment with dexamethasone alleviates symptoms of AMS/HACE but does not improve acclimatization. Dexamethasone is not a substitute for immediate descent in HACE.</p>
<p>§ May not require any pharmacologic intervention. In proper setting, rest and supplemental oxygen may be sufficient. Refer to accompanying UpToDate text.</p>
¥ In children, descent and/or supplemental oxygen are preferred treatment and often effective without pharmacologic therapy. Compared with nifedipine, amlodipine offers advantages for small children because of once daily dosing and availability as liquid or appropriately sized tablets, but it has not been studied specifically in children for HAPE treatment. Dosing is based on pediatric pulmonary hypertension management guidelines and expert opinion.</div><div class="graphic_reference">Courtesy of Scott Gallagher, MD and Peter Hackett, MD, with additional data from:
<ol>
<li>Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update. Wilderness Environ Med 2019; 30:S3.</li>
<li>Pollard A, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol 2001; 2:389.</li>
<li>Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015; 132:2037.</li>
</ol></div><div id="graphicVersion">Graphic 76719 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
